Companies › Pyrotech Therapeutics
2 active drug programs in 2 registered trials: 2 Phase 1; Other, Oncology; next expected readout Aug 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| PTT-121 | – | Phase 1 | Healthy Vollunteer | Aug 2027 |
| PTT-936 Alpha Kinase 1 (ALPK1) activator | ALPK1 | Phase 1 | Locally Advanced or Metastatic Solid Tumors | Sep 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07768176 | PTT-121 | Phase 1 | Healthy Vollunteer | Other | Aug 2027 |
| NCT06244992 | PTT-936 | Phase 1 | Locally Advanced or Metastatic Solid Tumors | Oncology | Sep 2027 |
Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm)
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.